文献速递淋巴瘤

Bcl-2与NFκB联合抑制协同诱导皮肤T细胞淋巴瘤细胞死亡

Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma.
PubMed 文献 · Blood · 2019-06-05

本研究探索Bcl-2抑制剂ABT-199与NF-κB抑制剂DMF联合治疗皮肤T细胞淋巴瘤(CTCL)。体外实验显示联合治疗对CTCL患者原代CD4+细胞及SeAx细胞系产生协同细胞死亡,体内异种移植小鼠模型中联合治疗减少肿瘤生长并延长总生存,疗效与耐受性均优于ABT-199单药。

要点

  • ABT-199和ABT-263在体外诱导CTCL患者原代CD4+细胞及SeAx细胞系特异性死亡,对健康供者T细胞及缺乏Bcl-2的HH细胞系无此作用。
  • ABT-199与DMF联合通过两条独立信号通路协同诱导CTCL细胞死亡。
  • 异种移植小鼠模型中,ABT-199联合DMF减少肿瘤生长并延长总生存,疗效与耐受性均优于ABT-199单药。

核心结论

  • Bcl-2与NF-κB抑制剂联合在CTCL中具有治疗潜力的概念验证,值得进一步临床研究。

研究设计与样本

  • 体外实验使用CTCL患者原代CD4+细胞、CTCL细胞系SeAx和HH及健康供者T细胞;体内使用CTCL异种移植小鼠模型。

主要发现

  • ABT-199和ABT-263在体外诱导CTCL患者原代CD4+细胞及SeAx细胞系特异性细胞死亡,但不诱导健康供者T细胞或缺乏Bcl-2的HH细胞系死亡。
  • ABT-199与DMF联合在CTCL细胞中通过两条独立信号通路协同诱导细胞死亡。
  • 异种移植小鼠模型中,ABT-199联合DMF有效减少肿瘤生长并延长总生存,通过协同诱导CTCL细胞死亡和抑制肿瘤细胞增殖实现。
  • 联合治疗在疗效和耐受性两方面均优于ABT-199单药。

临床怎么用

  • 原文提出Bcl-2与NF-κB抑制剂联合治疗CTCL的潜力应进一步在临床研究中探索。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapeutic options for cutaneous T-cell lymphoma (CTCL) are limited and curative treatment regimens are not available. Thus, new targeted and well-tolerated therapeutic approaches are urgently needed. In this respect, we have recently shown that dimethyl fumerate (DMF) inhibits NF-κB acting as a survival factor in CTCL. Similarly, inhibition of the antiapoptotic protein B-cell lymphoma 2 (Bcl-2) has been shown to induce cell death in CTCL especially when combined with histone deacetylase inhibitors. Therefore, we hypothesized that inhibition of Bcl-2 should potentiate NF-κB inhibition in a novel combination treatment of CTCL. We show that, in vitro, the Bcl-2 inhibitors ABT-199 and ABT-263 induced specific cell death in primary CD4+ cells from CTCL patients as well as in the CTCL cell line SeAx, but not in T cells of healthy donors nor in the CTCL cell line HH, which lacks Bcl-2. Combined treatment with ABT-199 and DMF caused synergistic cell death specifically in CTCL cells engaging 2 independent signaling pathways. To verify these findings in vivo, we performed combined ABT-199 and DMF treatment in a xenograft mouse model for CTCL. The combined treatment effectively reduced tumor growth and increased overall survival via synergistic induction of CTCL cell death and suppression of tumor cell proliferation. Essentially, the combination treatment was superior to ABT-199 monotherapy with respect to both efficacy and tolerability. To sum up, our data provide proof of principle for the therapeutic potential of combining Bcl-2 and NF-κB inhibitors in treating CTCL. Next, this potential should be explored further in a clinical study.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Froehlich TC, Müller-Decker K, Braun JD, et al. Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma. Blood. 2019. PMID: 31167801. doi:10.1182/blood.2019001545

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。